SOURCE: ChromoCure, Inc.

March 30, 2010 09:00 ET

ChromoCure Enters Into Technology Exchange and Collaboration Agreement With Genome Research Group to Acquire Therapeutic Modeling Protocols and Algorithms

RENO, NV--(Marketwire - March 30, 2010) -  ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure, announced today the signing of a Joint Venture and Technology Sharing Agreement with Genome Research Group (GRG). Under the Agreement ChromoCure will have access to GRG's proprietary advanced therapeutic modeling protocols and algorithms utilizing hypothermic modulation and resonance for the non-toxic and non-invasive treatment of cancer. 

GRG will have complete access to the Company's chromosomal scanner technology including a complex and innovative series of systems, processes, cell preparation techniques and diagnostic algorithms. GRG will use the company's technology for on-demand, real-time cancer progression analysis to monitor and determine treatment efficacy.

GRG's advanced Therapeutic Modeling Protocols, together with ChromoCure's landmark Chromosomal Scanning Technology, further strengthens the Company's leadership in Cancer Detection, Therapy and Cure, and puts new impetus to its groundbreaking Project Boveri: Finding the Cure.

The Agreement will provide ChromoCure access to the following:

  • hypothermic modulation and resonance protocols
  • systems engineering specifications for human and animal applications
  • remission monitoring protocols, procedures, and remission predictors
  • tumor therapeutic growth and remission projection models
  • remission estimation and projection models
  • cancer stage analysis measurement and prediction model
  • animal tumor eradication models and remission protocol models
  • animal metastasis prediction technology and equations
  • metastasis remission protocol and projection analysis
  • leukemia progression prediction and measurement, metastasis reversion procedures

The Agreement is a further step in the Company's transition to a focused Cancer Therapy and Cure Research & Development organization. The Company recently announced its accelerated Therapy and Cure initiatives through the launch of Project Boveri: Find the Cure, properly reflecting its pioneering role in cancer detection, therapy and cure and its increased research programs and collaborations.

The Company's proprietary Chromosomal Scanner systems have proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has been proven to have an effective accuracy of 100% for all cancers at all stages. This is superior to other detection approaches presently relied upon by pathologists, including genetic or protein biomarker detection.

ChromoCure's systems measure aneuploidy as the sole means of detecting cancer presence and measuring cancer progression. The system has a 100% effective accuracy rate. The Company recently published its collaborative clinical testing with a major cancer clinic.

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems and related therapeutic technologies. The Company's proprietary CS200 Chromosomal Scanner has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's detection technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure. The Company also applies its technology and knowledge to cancer cure and therapeutics research.

Safe-Harbor Statement

This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.

Contact Information